Clinical Trial Update: Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating interleukin-21 expanded natural killer cells for induction therapy in acute myeloid leukemia (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• interleukin-21 expanded natural killer cells (interleukin-21 expanded natural killer cells)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN